85
Participants
Start Date
February 28, 2009
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
Lenalidomide
"1. Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~2. Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~3. Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
Institut Paoli Calmettes, Marseille
CH de Valence, Valence
Hopital Purpan Service d'Hématologie Clinique, Toulouse
Centre Hospitalier de Lens, Lens
CHU Haut-Lévèque, Bordeaux
CHU de nantes, Nantes
CHU Brabois, Nancy
centre hospitalier de Lens, Lens
CHU de Clermont-Ferrand, Clermont-Ferrand
Centre Hospitalier de La Cote Basque, Bayonne
Centre Hospitalier Joffre, Perpignan
Hôpital Hautepierre, Strasbourg
Centre Hospitalier Lyon Sud, Lyon
Centre Hospitalier du Mans, Le Mans
Centre hospitalier de Chambéry, Chambéry
Hoiptal St Louis, Paris
Hopital Cochin-Hematology, Paris
Centre Henri Becquerel, Rouen
Hôpital Limoges, Limoges
Centre henri Mondor, Créteil
Institut gustave Roussy, Villejuif
hopital Victor Dupouy, Argenteuil
CH Angers, Angers
Hôpital Avicenne, Bobigny
Hôpital Archet1, Nice
Collaborators (1)
Celgene Corporation
INDUSTRY
Groupe Francophone des Myelodysplasies
OTHER